JP2009005695A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009005695A5 JP2009005695A5 JP2008149091A JP2008149091A JP2009005695A5 JP 2009005695 A5 JP2009005695 A5 JP 2009005695A5 JP 2008149091 A JP2008149091 A JP 2008149091A JP 2008149091 A JP2008149091 A JP 2008149091A JP 2009005695 A5 JP2009005695 A5 JP 2009005695A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding portion
- monoclonal antibody
- antibody
- madcam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (48)
- 重鎖が、それぞれSEQ ID NO:34の50〜54、69〜85、および118〜132番目のアミノ酸配列を有する抗体の重鎖CDR1、CDR2およびCDR3を含む、および軽鎖が、それぞれSEQ ID NO:36の44〜59、75〜81、および114〜122番目のアミノ酸配列を有する抗体の軽鎖CDR1、CDR2およびCDR3を含む、粘膜アドレシン細胞接着分子(MAdCAM)へ特異的に結合する、モノクローナル抗体またはその抗原結合部分。
- ヒトVH 1-18遺伝子を利用する重鎖を含む、請求項1記載のモノクローナル抗体または抗原結合部分。
- ヒトVk A2遺伝子を利用する軽鎖を含む、請求項１または２記載のモノクローナル抗体または抗原結合部分。
- 以下を含む、 MAdCAMへ特異的に結合するモノクローナル抗体またはその抗原結合部分：
SEQ ID NO:34の20〜144番目のアミノ酸配列を有する重鎖可変ドメインを含む重鎖、および
SEQ ID NO:36の21〜133番目のアミノ酸配列を有する軽鎖可変ドメインを含む軽鎖。 - CDR以外のアミノ酸配列に1つまたは複数のアミノ酸置換、付加、または欠失を有するSEQ ID NO:34の20〜144番目のアミノ酸配列を有する抗体の重鎖可変ドメインを含む重鎖と、CDR以外のアミノ酸配列に1つまたは複数のアミノ酸置換、付加、または欠失を有するSEQ ID NO:36の21〜133番目のアミノ酸配列を有する抗体の軽鎖可変ドメインを含む軽鎖とを含む、 MAdCAMへ特異的に結合するモノクローナル抗体またはその抗原結合部分。
- (a)重鎖がSEQ ID NO: 34のアミノ酸20〜469からなり、
(b)軽鎖がSEQ ID NO: 36のアミノ酸21〜239からなる、
MAdCAMへ特異的に結合するモノクローナル抗体またはその抗原結合部分。 - 免疫グロブリンG(IgG)、IgM、IgE、およびIgAもしくはIgDである、請求項1〜5のいずれか一項記載のモノクローナル抗体。
- Fab断片、F(ab')2断片、Fv断片または一本鎖抗体である、請求項1〜5のいずれか一項記載の抗原結合部分。
- 請求項1〜６のいずれか一項記載のモノクローナル抗体または抗原結合部分の有効量および薬学的に許容される担体を含む薬学的組成物。
- 請求項1〜６のいずれか一項記載のモノクローナル抗体またはその抗原結合部分を含む、MAdCAMのα 4 β 7 への結合を阻害することにより炎症性疾患を処置するための組成物。
- 炎症性疾患が胃腸管の炎症性疾患である、請求項10記載の組成物。
- 胃腸管の炎症性疾患が、炎症性腸疾患、クローン病、潰瘍性大腸炎、憩室疾患、胃炎、肝臓疾患、原発性胆汁性硬化症および硬化性胆管炎からなる群より選択される、請求項11記載の組成物。
- 炎症性疾患が、クローン病または潰瘍性大腸炎である、請求項10記載の組成物。
- 炎症性疾患がインスリン依存性糖尿病または移植片対宿主病である、請求項10記載の組成物。
- 請求項1〜６のいずれか一項記載のモノクローナル抗体または抗原結合部分、または該抗体もしくは該部分の重鎖もしくは軽鎖を産生する単離された細胞系。
- モノクローナル抗体7.16.6 （European Collection of Cell Cultures (ECACC)アクセッション番号 03090909）、または該モノクローナル抗体7.16.6のアミノ酸配列を含む抗体を産生する、請求項１５記載の細胞系。
- 請求項1〜６のいずれか一項記載の抗体の重鎖もしくはその抗原結合部分、または軽鎖もしくはその抗原結合部分をコードするヌクレオチド配列を含む単離された核酸分子。
- 核酸分子に機能的に連結された発現制御配列を任意で含む、請求項17記載の核酸分子を含むベクター。
- 請求項18記載のベクターまたは請求項17記載の核酸分子を含む宿主細胞。
- 請求項1〜６のいずれか一項記載の抗体の、重鎖もしくはその抗原結合部分をコードする核酸分子、ならびに軽鎖もしくはその抗原結合部分をコードする核酸分子を含む、請求項19記載の宿主細胞。
- MAdCAMに特異的に結合するヒトモノクローナル抗体またはその抗原結合部分を作製する方法であって、請求項19もしくは20記載の宿主細胞または請求項15もしくは16のいずれか記載の細胞系を適した条件下で培養する段階、および該抗体または抗原結合部分を回収する段階を含む、方法。
- 請求項1〜６のいずれか一項記載の抗体の、重鎖もしくはその抗原結合部分をコードする核酸分子と、軽鎖もしくはその抗原結合部分をコードする核酸分子を含む、非ヒトトランスジェニック動物またはトランスジェニック植物であって、該核酸分子にコードされる該重鎖および軽鎖を発現させる、非ヒトトランスジェニック動物またはトランスジェニック植物。
- 請求項22記載の非ヒトトランスジェニック動物またはトランスジェニック植物から抗体を単離する段階を含む、MAdCAMへ特異的に結合する抗体またはその抗原結合部分を単離する方法。
- 請求項1〜６のいずれか一項記載のモノクローナル抗体または抗原結合部分を含む、ヒトMAdCAMを発現させる細胞へのα4β7の結合を阻害する組成物。
- 請求項1〜６のいずれか一項記載のモノクローナル抗体または抗原結合部分を含む、MAdCAM媒介性白血球内皮細胞接着を阻害するための組成物。
- 請求項1〜６のいずれか一項記載のモノクローナル抗体または抗原結合部分を含む、組織へのMAdCAM媒介性白血球の接着、遊走および浸潤を阻害するための組成物。
- 請求項1〜６のいずれか一項記載のモノクローナル抗体または抗原結合部分を含む、α4β7/MAdCAM依存性細胞接着を阻害するための組成物。
- 請求項1〜６のいずれか一項記載のモノクローナル抗体または抗原結合部分を含む、リンパ球の胃腸リンパ組織へのMAdCAM媒介性補充を阻害するための組成物。
- (1)生体試料を請求項1〜６のいずれか一項記載のモノクローナル抗体または抗原結合部分と接触させる段階、ならびに(2)該生体試料における該抗体または抗原結合部分のMAdCAMへの結合を検出する段階を含む、循環している可溶性ヒトMAdCAMを特徴とする疾患を診断するための方法。
- 抗体が、それぞれSEQ ID NO:34の20〜49、55〜68、86〜117、および 133〜144番目のアミノ酸配列を有する重鎖FR1、FR2、FR3、およびFR4の１つまたは複数を含む、並びにそれぞれSEQ ID NO:36の21〜43、60〜74、82〜113、および123〜133番目のアミノ酸配列を有する抗体の軽鎖FR1、FR2、FR3、およびFR4の１つまたは複数を含む、請求項１記載のモノクローナル抗体または抗原結合部分。
- 請求項1〜６のいずれか一項記載のモノクローナル抗体または抗原結合部分であって、該抗体またはその部分が検出可能に標識されている、被験者において炎症を検出するための組成物。
- 請求項1〜６のいずれか一項記載のモノクローナル抗体または抗原結合部分を含む診断キット。
- 1つもしくは複数の追加の抗炎症性剤または免疫調節剤をさらに含む、請求項９記載の薬学的組成物。
- 1つもしくは複数の追加の抗炎症性剤または免疫調節剤が以下のものからなる群より選択される、請求項33記載の薬学的組成物：コルチコステロイド、アミノサリチラート、アザチオプリン、メトトレキセート、シクロスポリン、FK506、IL-10、GM-CSF、ラパマイシン、抗TNFα剤、および接着分子アンタゴニスト。
- 循環しているα 4 β 7 発現白血球のレベルにおける増加があるかどうかを測定し、それにより阻害性抗MAdCAM抗体またはその抗原結合部分の被験者への投与の効果を検出するための組成物であって、請求項1〜６のいずれか一項記載のモノクローナル抗体または抗原結合部分を含む、前記組成物。
- 白血球がリンパ球である、請求項35記載の方法。
- 循環しているα4β7発現白血球のレベルにおける増加がFACS分析により測定される、請求項35記載の組成物。
- MAdCAMのα 4 β 7 への結合を阻害することにより炎症性疾患を処置するための医薬の製造における、請求項1〜６のいずれか一項記載のモノクローナル抗体または抗原結合部分の使用。
- 炎症性疾患が胃腸管の炎症性疾患である、請求項38記載の使用。
- 胃腸管の炎症性疾患が、炎症性腸疾患、クローン病、潰瘍性大腸炎、憩室疾患、胃炎、肝臓疾患、原発性胆汁性硬化症および硬化性胆管炎からなる群より選択される、請求項39記載の使用。
- 炎症性疾患が、クローン病または潰瘍性大腸炎である、請求項38記載の組成物。
- 炎症性疾患がインスリン依存性糖尿病または移植片対宿主病である、請求項38記載の使用。
- 被験者において炎症を検出するための医薬の製造における、請求項1〜６のいずれか一項記載のモノクローナル抗体または抗原結合部分の使用。
- 循環しているα 4 β 7 発現白血球のレベルにおける増加があるかどうかを測定し、それにより阻害性抗MAdCAM抗体またはその抗原結合部分の被験者への投与の効果を検出するためのするための医薬の製造における、請求項1〜６のいずれか一項記載のモノクローナル抗体または抗原結合部分の使用。
- 白血球がリンパ球である、請求項44記載の使用。
- 循環しているα 4 β 7 発現白血球のレベルにおける増加がFACS分析により測定される、請求項44記載の使用。
- ハイブリドーマが1.7.2(ECACCアクセッション番号03090901)、1.8.2(ECACCアクセッション番号03090902)、6.14.2(ECACCアクセッション番号03090903)、6.22.2(ECACCアクセッション番号03090904)、6.34.2(ECACCアクセッション番号03090905)、6.67.1(ECACCアクセッション番号03090906)、6.73.2(ECACCアクセッション番号03090907)、6.77.1(ECACCアクセッション番号03090908)、7.20.5(ECACCアクセッション番号03090910)、7.26.4(ECACCアクセッション番号03090911)、および9.8.2(ECACCアクセッション番号03090912)からなる群より選択される、ハイブリドーマ細胞系。
- 請求項47記載のハイブリドーマ細胞系により産生されるヒトモノクローナル抗体、または該モノクローナル抗体の抗原結合部分。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53549004P | 2004-01-09 | 2004-01-09 | |
| US60/535,490 | 2004-01-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006549399A Division JP4315982B2 (ja) | 2004-01-09 | 2005-01-07 | ＭＡｄＣＡＭに対する抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009260786A Division JP5094818B2 (ja) | 2004-01-09 | 2009-11-16 | ＭＡｄＣＡＭに対する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009005695A JP2009005695A (ja) | 2009-01-15 |
| JP2009005695A5 true JP2009005695A5 (ja) | 2009-04-23 |
| JP4729076B2 JP4729076B2 (ja) | 2011-07-20 |
Family
ID=34794356
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006549399A Active JP4315982B2 (ja) | 2004-01-09 | 2005-01-07 | ＭＡｄＣＡＭに対する抗体 |
| JP2008149091A Active JP4729076B2 (ja) | 2004-01-09 | 2008-06-06 | ＭＡｄＣＡＭに対する抗体 |
| JP2009260786A Active JP5094818B2 (ja) | 2004-01-09 | 2009-11-16 | ＭＡｄＣＡＭに対する抗体 |
| JP2012154794A Active JP5836896B2 (ja) | 2004-01-09 | 2012-07-10 | ＭＡｄＣＡＭに対する抗体 |
| JP2015138764A Active JP6215875B2 (ja) | 2004-01-09 | 2015-07-10 | ＭＡｄＣＡＭに対する抗体 |
| JP2017004899A Active JP6423024B2 (ja) | 2004-01-09 | 2017-01-16 | ＭＡｄＣＡＭに対する抗体 |
| JP2018087973A Active JP6637104B2 (ja) | 2004-01-09 | 2018-05-01 | ＭＡｄＣＡＭに対する抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006549399A Active JP4315982B2 (ja) | 2004-01-09 | 2005-01-07 | ＭＡｄＣＡＭに対する抗体 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009260786A Active JP5094818B2 (ja) | 2004-01-09 | 2009-11-16 | ＭＡｄＣＡＭに対する抗体 |
| JP2012154794A Active JP5836896B2 (ja) | 2004-01-09 | 2012-07-10 | ＭＡｄＣＡＭに対する抗体 |
| JP2015138764A Active JP6215875B2 (ja) | 2004-01-09 | 2015-07-10 | ＭＡｄＣＡＭに対する抗体 |
| JP2017004899A Active JP6423024B2 (ja) | 2004-01-09 | 2017-01-16 | ＭＡｄＣＡＭに対する抗体 |
| JP2018087973A Active JP6637104B2 (ja) | 2004-01-09 | 2018-05-01 | ＭＡｄＣＡＭに対する抗体 |
Country Status (38)
| Country | Link |
|---|---|
| US (6) | US9328169B2 (ja) |
| EP (2) | EP2177537B1 (ja) |
| JP (7) | JP4315982B2 (ja) |
| KR (2) | KR20120048644A (ja) |
| CN (1) | CN1956738B (ja) |
| AP (1) | AP2006003689A0 (ja) |
| AR (1) | AR047372A1 (ja) |
| AT (2) | ATE522547T1 (ja) |
| AU (1) | AU2005204678B2 (ja) |
| BR (2) | BRPI0506768B1 (ja) |
| CA (1) | CA2552523C (ja) |
| CR (1) | CR8485A (ja) |
| DE (1) | DE602005026779D1 (ja) |
| DK (1) | DK2177537T3 (ja) |
| DO (1) | DOP2005000002A (ja) |
| EA (1) | EA012872B1 (ja) |
| EC (1) | ECSP066741A (ja) |
| ES (2) | ES2372733T3 (ja) |
| HK (1) | HK1099695A1 (ja) |
| IL (1) | IL176749A0 (ja) |
| MA (1) | MA28430B1 (ja) |
| MX (4) | MX350383B (ja) |
| MY (1) | MY140862A (ja) |
| NL (1) | NL1027975C2 (ja) |
| NO (1) | NO342054B1 (ja) |
| NZ (1) | NZ548702A (ja) |
| OA (1) | OA13358A (ja) |
| PA (1) | PA8621301A1 (ja) |
| PE (1) | PE20051053A1 (ja) |
| PL (1) | PL2177537T3 (ja) |
| PT (1) | PT2177537E (ja) |
| SI (1) | SI2177537T1 (ja) |
| SV (1) | SV2006001990A (ja) |
| TN (1) | TNSN06216A1 (ja) |
| TW (2) | TWI366570B (ja) |
| UY (1) | UY28716A1 (ja) |
| WO (1) | WO2005067620A2 (ja) |
| ZA (1) | ZA200605825B (ja) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL228041B1 (pl) | 2001-01-05 | 2018-02-28 | Amgen Fremont Inc | Przeciwciało przeciwko receptorowi insulinopodobnego czynnika wzrostu I, zawierajaca go kompozycja farmaceutyczna, sposób jego wytwarzania, zastosowania, linia komórkowa, wyizolowana czasteczka kwasu nukleinowego, wektor, komórka gospodarza oraz zwierze transgeniczne. |
| US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| NZ582210A (en) * | 2003-02-13 | 2011-04-29 | Pfizer Prod Inc | Uses of anti-insulin-like growth factor I receptor antibodies |
| EP1664322B1 (en) | 2003-05-22 | 2013-07-10 | Fraunhofer USA, Inc. | Recombinant carrier molecule for expression, delivery and purification of target polypeptides |
| MX350383B (es) | 2004-01-09 | 2017-09-04 | Pfizer | Anticuerpos contra madcam. |
| RU2453558C2 (ru) | 2004-09-03 | 2012-06-20 | Дженентек, Инк. | Гуманизированные антагонистические антитела против бета7 и их применение |
| NZ561137A (en) * | 2005-03-08 | 2011-09-30 | Pharmacia & Upjohn Co Llc | Stable anti-CTLA-4 antibody compositions with chelating agents |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| JP2009500390A (ja) * | 2005-07-08 | 2009-01-08 | ファイザー・リミテッド | 新規ＭＡｄＣＡＭ抗体 |
| US20090214527A1 (en) * | 2005-07-11 | 2009-08-27 | Gary Burgess | Combination Of Anti-Madcam Antibody And Antifibrotic Caspase Inhibitor To Treat Liver Fibrosis |
| WO2007007151A2 (en) * | 2005-07-11 | 2007-01-18 | Pfizer Limited | Use of anti-mad-cam antibody for the treatment of emphysema |
| WO2007007160A2 (en) * | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat fever |
| WO2007117264A2 (en) | 2005-08-03 | 2007-10-18 | Fraunhofer Usa, Inc. | Compositions and methods for production of immunoglobulins |
| ES2654040T3 (es) | 2006-03-31 | 2018-02-12 | Chugai Seiyaku Kabushiki Kaisha | Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos |
| WO2007114319A1 (ja) * | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 抗体の血中動態を制御する方法 |
| US7745584B2 (en) * | 2006-05-22 | 2010-06-29 | California Institute Of Technology | Antibodies to sulfated carbohydrates |
| EP1878747A1 (en) * | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
| JP2010503668A (ja) * | 2006-09-15 | 2010-02-04 | フラウンホーファー ユーエスエー， インコーポレイテッド | インフルエンザ抗体、組成物、および関連する方法 |
| CA2687141C (en) | 2007-05-22 | 2014-04-01 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| US8404252B2 (en) | 2007-07-11 | 2013-03-26 | Fraunhofer Usa, Inc. | Yersinia pestis antigens, vaccine compositions, and related methods |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| WO2009041613A1 (ja) | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | 抗体定常領域改変体 |
| US8912149B1 (en) | 2007-11-28 | 2014-12-16 | California Institute Of Technology | Glycosaminoglycan mimetics |
| ES2834741T3 (es) | 2007-12-05 | 2021-06-18 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-NR10 y uso del mismo |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| CN102124344B (zh) * | 2008-05-16 | 2015-04-01 | 霍夫曼-拉罗奇有限公司 | 生物标记用于评估β7整联蛋白拮抗剂治疗胃肠道炎性病症的用途 |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| WO2010037046A1 (en) | 2008-09-28 | 2010-04-01 | Fraunhofer Usa, Inc. | Humanized neuraminidase antibody and methods of use thereof |
| EP2409991B1 (en) | 2009-03-19 | 2017-05-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| TWI544077B (zh) | 2009-03-19 | 2016-08-01 | Chugai Pharmaceutical Co Ltd | Antibody constant region change body |
| TWI466681B (zh) | 2009-03-20 | 2015-01-01 | Amgen Inc | α４β７雜二聚體專一性拮抗抗體 |
| MX2011009798A (es) | 2009-03-20 | 2011-12-08 | Amgen Inc | Inmunoglobulinas portadoras y usos de las mismas. |
| BRPI1011145A2 (pt) | 2009-05-15 | 2016-03-15 | Chugai Pharmaceutical Co Ltd | anticorpo anti-axl |
| JP5837821B2 (ja) | 2009-09-24 | 2015-12-24 | 中外製薬株式会社 | 抗体定常領域改変体 |
| WO2011041391A1 (en) | 2009-09-29 | 2011-04-07 | Fraunhofer Usa, Inc. | Influenza hemagglutinin antibodies, compositions, and related methods |
| US20110158982A1 (en) * | 2009-10-05 | 2011-06-30 | The Regents Of The University Of Michigan | COMPOSITIONS AND METHODS FOR INHIBITING MAdCAM |
| US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
| US20130011406A1 (en) * | 2010-03-26 | 2013-01-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
| SG188591A1 (en) | 2010-09-22 | 2013-04-30 | Amgen Inc | Carrier immunoglobulins and uses thereof |
| KR101398363B1 (ko) | 2010-11-17 | 2014-05-22 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
| CN102603649B (zh) * | 2011-01-20 | 2016-05-25 | 赣南师范学院 | 一种以地巴唑为先导分子的荧光探针化合物及其制备方法 |
| EP2668210B1 (en) | 2011-01-26 | 2020-06-17 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
| MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| CN103596985B (zh) | 2011-04-19 | 2016-06-08 | 美国政府(由卫生和人类服务部的部长所代表) | 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途 |
| WO2012154987A1 (en) | 2011-05-10 | 2012-11-15 | Nestec Sa | Methods of disease activity profiling for personalized therapy management |
| US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| TWI593705B (zh) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
| SG11201500489YA (en) | 2012-07-25 | 2015-02-27 | Kolltan Pharmaceuticals Inc | Anti-kit antibodies and uses thereof |
| IL282082B (en) * | 2012-08-23 | 2022-08-01 | Seagen Inc | Antibody-drug conjugates (adc) binding to 158p1d7 proteins |
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| ES2901704T3 (es) | 2013-03-15 | 2022-03-23 | Protagonist Therapeutics Inc | Análogos de hepcidina y usos de los mismos |
| US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
| CN105517571A (zh) | 2013-06-24 | 2016-04-20 | 中外制药株式会社 | 含有人源化抗上皮调节蛋白抗体作为有效成分的腺癌以外的非小细胞肺癌的治疗药 |
| US9770461B2 (en) | 2013-08-02 | 2017-09-26 | California Institute Of Technology | Tailored glycopolymers as anticoagulant heparin mimetics |
| US10227370B2 (en) | 2013-08-02 | 2019-03-12 | California Institute Of Technology | Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity |
| US11427627B2 (en) | 2013-09-05 | 2022-08-30 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| RS58705B1 (sr) | 2013-09-20 | 2019-06-28 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| EP3050896B1 (en) | 2013-09-27 | 2021-07-07 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
| CA2949237C (en) | 2014-05-16 | 2022-08-23 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
| SG10201810321PA (en) | 2014-05-16 | 2018-12-28 | Protagonist Therapeutics Inc | α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS |
| CN113908269A (zh) | 2014-05-23 | 2022-01-11 | 塞尔德克斯医疗公司 | 嗜酸性粒细胞或肥大细胞相关病症的治疗 |
| SG10201810154WA (en) | 2014-07-17 | 2018-12-28 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| EP3201217A4 (en) | 2014-10-01 | 2018-07-18 | Protagonist Therapeutics Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
| EP3200812B8 (en) | 2014-10-01 | 2021-04-28 | Protagonist Therapeutics, Inc. | Novel alpha4beta7 peptide monomer and dimer antagonists |
| US20170327584A1 (en) | 2014-11-26 | 2017-11-16 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the Treatment of Fistulizing Crohn's Disease |
| MY183415A (en) | 2014-12-19 | 2021-02-18 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| SG11201700841QA (en) | 2014-12-19 | 2017-03-30 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| CA2916283A1 (en) * | 2015-01-09 | 2016-07-09 | Pfizer Inc. | Dosage regimen for madcam antagonists |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| BR112017014067B1 (pt) | 2015-02-27 | 2021-01-12 | Chugai Seiyaku Kabushiki Kaisha | usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6 |
| US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| WO2017115773A1 (ja) | 2015-12-28 | 2017-07-06 | 中外製薬株式会社 | Ｆｃ領域含有ポリペプチドの精製を効率化するための方法 |
| WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| US20190077868A1 (en) | 2016-03-14 | 2019-03-14 | Millennium Pharmaceuticals, Inc. | Methods of treating or preventing graft versus host disease |
| WO2017160699A2 (en) | 2016-03-14 | 2017-09-21 | Millennium Pharmaceuticals, Inc. | Method of preventing graft versus host disease |
| MX2018010988A (es) | 2016-03-14 | 2019-01-21 | Chugai Pharmaceutical Co Ltd | Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer. |
| CA3017926C (en) | 2016-03-23 | 2023-10-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing .alpha.4.beta.7 peptide antagonists |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| US11760803B2 (en) | 2016-03-24 | 2023-09-19 | Takeda Pharmaceutical Company Limited | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| MX2019001448A (es) | 2016-08-05 | 2019-09-13 | Chugai Pharmaceutical Co Ltd | Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8). |
| KR101877349B1 (ko) | 2016-08-05 | 2018-07-17 | 농업회사법인 주식회사 한라종합식품 | 황칠 구운 소금 제조방법 |
| MA47775A (fr) | 2017-03-14 | 2020-01-22 | Amgen Inc | Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire |
| EP3596108A4 (en) * | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| BR112019024127A2 (pt) * | 2017-05-24 | 2020-06-23 | Pandion Therapeutics, Inc. | Imunotolerância alvejada |
| MX2019012076A (es) | 2017-05-30 | 2019-12-09 | Bristol Myers Squibb Co | Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1). |
| MX2019012032A (es) | 2017-05-30 | 2019-10-30 | Bristol Myers Squibb Co | Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3). |
| US11162943B2 (en) | 2017-05-31 | 2021-11-02 | Prometheus Biosciences Inc. | Methods for assessing mucosal healing in Crohn's disease patients |
| WO2019014572A1 (en) | 2017-07-14 | 2019-01-17 | Pfizer, Inc. | ANTIBODIES DIRECTED AGAINST MADCAM |
| WO2019051494A1 (en) | 2017-09-11 | 2019-03-14 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND USES THEREOF |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| EP3720871A4 (en) * | 2017-12-06 | 2021-09-15 | Pandion Operations, Inc. | TARGETED IMMUNTOLERANCE |
| EP3753952A4 (en) | 2017-12-13 | 2022-04-13 | XDCExplorer (Shanghai) Co., Ltd. | EGFRVIII ANTIBODY AND CONJUGATE, METHOD FOR THE PREPARATION AND USE THEREOF |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| IL313983A (en) | 2018-03-26 | 2024-08-01 | Amgen Inc | Fully fucose-free glycoforms of antibodies are produced in cell culture |
| WO2020061142A1 (en) * | 2018-09-18 | 2020-03-26 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| EP3972992A4 (en) * | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | ANTI-MADCAM IMMUNE TOLERANCE |
| MX2022000397A (es) | 2019-07-10 | 2022-04-25 | Protagonist Therapeutics Inc | Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
| CA3152547A1 (en) | 2019-09-26 | 2021-04-01 | Amgen Inc. | Methods of producing antibody compositions |
| CN110887966B (zh) * | 2019-12-17 | 2021-02-12 | 丹娜(天津)生物科技股份有限公司 | 一种曲霉菌的化学发光检测试剂盒及其应用 |
| WO2021146454A1 (en) | 2020-01-15 | 2021-07-22 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US11845808B2 (en) | 2020-01-15 | 2023-12-19 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| CN111714781B (zh) * | 2020-06-24 | 2022-08-05 | 北京夏禾科技有限公司 | 一种牙齿美白组合及其使用方法 |
| EP4229080A1 (en) | 2020-10-15 | 2023-08-23 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
| WO2022109328A1 (en) | 2020-11-20 | 2022-05-27 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| AR126089A1 (es) | 2021-06-07 | 2023-09-13 | Amgen Inc | Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas |
| IL309631A (en) * | 2021-06-21 | 2024-02-01 | Roussy Inst Gustave | Methods for diagnosing cancer- or antibiotic-induced dysbiosis and their use for improving cancer treatment by immunotherapy |
| CA3233279A1 (en) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
| US12112433B2 (en) * | 2022-04-06 | 2024-10-08 | Qualcomm Incorporated | Apparatus and methods for image reconstruction using machine learning processes |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| US20240166746A1 (en) | 2022-11-22 | 2024-05-23 | Takeda Pharmaceutical Company Limited | DOSAGE REGIMEN OF MAdCAM-1 ANTIBODY FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| US5151540A (en) * | 1986-11-26 | 1992-09-29 | Hoechst Celanese Corporation | Thio carbamates and their derivatives |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US20040010810A1 (en) | 1990-01-12 | 2004-01-15 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| JP3068180B2 (ja) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | 異種抗体の生成 |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE352612T1 (de) | 1990-08-29 | 2007-02-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5462990A (en) * | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| ATE363532T1 (de) | 1991-03-01 | 2007-06-15 | Dyax Corp | Verfahren zur herstellung bindender miniproteine |
| ES2315612T3 (es) | 1991-04-10 | 2009-04-01 | The Scripps Research Institute | Genotecas de receptores heterodimericos usando fagemidos. |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| DE69331089T2 (de) | 1992-02-18 | 2002-07-18 | Otsuka Kagaku K.K., Osaka | Beta-Laktam und Cepham Verbindungen und Ihre Herstellung |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| WO1994013312A1 (en) | 1992-12-15 | 1994-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Mucosal vascular addressin, dna and expression |
| JP3801196B2 (ja) | 1993-03-09 | 2006-07-26 | ジェンザイム・コーポレイション | 乳からの対象化合物の単離 |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| US7750137B2 (en) | 1995-09-01 | 2010-07-06 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins |
| DE69637155T2 (de) | 1995-02-10 | 2008-02-07 | Millennium Pharmaceuticals, Inc., Cambridge | Addressine der schleimhaut und der blutgefässe und ihre verwendung |
| US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| WO1996033266A1 (en) | 1995-04-21 | 1996-10-24 | Cell Genesys, Inc. | Generation of large genomic dna deletions |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69636868T2 (de) | 1995-08-29 | 2007-10-25 | Kirin Beer Kabushiki Kaisha | Chimäres tier und methode zu dessen herstellung |
| US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| KR20080059467A (ko) | 1996-12-03 | 2008-06-27 | 아브게닉스, 인크. | 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| KR20010034554A (ko) | 1998-03-03 | 2001-04-25 | 레이몬드, 엠. 위티 | 치료제로서의 ｃｄ147 결합 분자 |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| US7090845B2 (en) | 1998-05-13 | 2006-08-15 | Genentech, Inc. | Diagnosis and treatment of hepatic disorders |
| WO1999058573A1 (en) * | 1998-05-13 | 1999-11-18 | Genentech, Inc. | Diagnosis and treatment of hepatic disorders |
| AU770555B2 (en) | 1998-08-17 | 2004-02-26 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| CZ303703B6 (cs) | 1998-12-23 | 2013-03-20 | Pfizer Inc. | Monoklonální protilátka nebo její antigen-vázající fragment, farmaceutická kompozice obsahující tuto protilátku nebo fragment, bunecná linie produkující tuto protilátku nebo fragment, zpusob prípravy této protilátky, izolovaná nukleová kyselina kóduj |
| EP1212407A4 (en) | 1999-09-03 | 2003-04-02 | Human Genome Sciences Inc | POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES OF THE IMMUNOGLOBULIN SUPERFAMILY |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| JP2003089656A (ja) * | 2001-09-19 | 2003-03-28 | Nippon Kayaku Co Ltd | 移植による免疫反応抑制剤 |
| CA2466034C (en) | 2001-11-08 | 2012-12-18 | Protein Design Labs, Inc. | Stable aqueous pharmaceutical formulations of daclizumab antibodies |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| IL163725A0 (en) | 2002-02-25 | 2005-12-18 | Elan Pharm Inc | Administration of agents for the treatment of inflammation |
| WO2004081049A1 (en) * | 2003-03-10 | 2004-09-23 | Auckland Uniservices Limited | Monoclonal antibodies that recognise mucosal addressin cell adhesion molecule-1 (madcam-1), soluble madcam-1 and uses thereof |
| PL1610820T5 (pl) | 2003-04-04 | 2014-01-31 | Genentech Inc | Preparaty zawierające wysokoskoncentrowane przeciwciała i białka |
| MX350383B (es) | 2004-01-09 | 2017-09-04 | Pfizer | Anticuerpos contra madcam. |
| EP2394652A3 (en) | 2004-02-06 | 2012-10-24 | Elan Pharmaceuticals Inc. | Methods and compositions for treating tumors and metastatic disease |
| NZ561137A (en) | 2005-03-08 | 2011-09-30 | Pharmacia & Upjohn Co Llc | Stable anti-CTLA-4 antibody compositions with chelating agents |
| US20100119517A1 (en) | 2005-07-08 | 2010-05-13 | Pfizer Inc | Use of Anti-MAdCAM Antibodies for the Treatment of Coeliac Disease and Tropical Sprue |
| JP2009500390A (ja) | 2005-07-08 | 2009-01-08 | ファイザー・リミテッド | 新規ＭＡｄＣＡＭ抗体 |
| WO2007007152A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat metastatic cancers and chloroma |
| WO2007007159A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat uterine disorders |
| WO2007007151A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Use of anti-mad-cam antibody for the treatment of emphysema |
| WO2007007160A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat fever |
| US20090214527A1 (en) | 2005-07-11 | 2009-08-27 | Gary Burgess | Combination Of Anti-Madcam Antibody And Antifibrotic Caspase Inhibitor To Treat Liver Fibrosis |
-
2005
- 2005-01-07 MX MX2014007315A patent/MX350383B/es unknown
- 2005-01-07 AR ARP050100053A patent/AR047372A1/es active IP Right Grant
- 2005-01-07 AP AP2006003689A patent/AP2006003689A0/xx unknown
- 2005-01-07 TW TW101100882A patent/TWI366570B/zh active
- 2005-01-07 EA EA200601297A patent/EA012872B1/ru not_active IP Right Cessation
- 2005-01-07 EP EP10150359A patent/EP2177537B1/en active Active
- 2005-01-07 ZA ZA200605825A patent/ZA200605825B/en unknown
- 2005-01-07 AT AT10150359T patent/ATE522547T1/de active
- 2005-01-07 MX MXPA06007843A patent/MXPA06007843A/es active IP Right Grant
- 2005-01-07 PA PA20058621301A patent/PA8621301A1/es unknown
- 2005-01-07 BR BRPI0506768-5A patent/BRPI0506768B1/pt active IP Right Grant
- 2005-01-07 NZ NZ548702A patent/NZ548702A/en unknown
- 2005-01-07 EP EP05711290A patent/EP1709080B1/en active Active
- 2005-01-07 NL NL1027975A patent/NL1027975C2/nl not_active IP Right Cessation
- 2005-01-07 JP JP2006549399A patent/JP4315982B2/ja active Active
- 2005-01-07 KR KR1020127004435A patent/KR20120048644A/ko not_active Application Discontinuation
- 2005-01-07 TW TW094100530A patent/TWI363762B/zh active
- 2005-01-07 SI SI200531421T patent/SI2177537T1/sl unknown
- 2005-01-07 CN CN2005800021223A patent/CN1956738B/zh active Active
- 2005-01-07 DE DE602005026779T patent/DE602005026779D1/de active Active
- 2005-01-07 MX MX2017011253A patent/MX370489B/es unknown
- 2005-01-07 MY MYPI20050059A patent/MY140862A/en unknown
- 2005-01-07 BR BR122021007893-9A patent/BR122021007893B1/pt active IP Right Grant
- 2005-01-07 PE PE2005000045A patent/PE20051053A1/es active IP Right Grant
- 2005-01-07 CA CA2552523A patent/CA2552523C/en active Active
- 2005-01-07 ES ES10150359T patent/ES2372733T3/es active Active
- 2005-01-07 SV SV2005001990A patent/SV2006001990A/es not_active Application Discontinuation
- 2005-01-07 AT AT05711290T patent/ATE501174T1/de not_active IP Right Cessation
- 2005-01-07 OA OA1200600223A patent/OA13358A/en unknown
- 2005-01-07 PL PL10150359T patent/PL2177537T3/pl unknown
- 2005-01-07 AU AU2005204678A patent/AU2005204678B2/en active Active
- 2005-01-07 PT PT10150359T patent/PT2177537E/pt unknown
- 2005-01-07 DK DK10150359.7T patent/DK2177537T3/da active
- 2005-01-07 US US11/031,485 patent/US9328169B2/en active Active
- 2005-01-07 UY UY28716A patent/UY28716A1/es unknown
- 2005-01-07 DO DO2005000002A patent/DOP2005000002A/es unknown
- 2005-01-07 WO PCT/US2005/000370 patent/WO2005067620A2/en active Application Filing
- 2005-01-07 ES ES05711290T patent/ES2362667T3/es active Active
-
2006
- 2006-06-26 CR CR8485A patent/CR8485A/es not_active Application Discontinuation
- 2006-07-07 TN TNP2006000216A patent/TNSN06216A1/en unknown
- 2006-07-07 MX MX2019015195A patent/MX2019015195A/es unknown
- 2006-07-09 IL IL176749A patent/IL176749A0/en active IP Right Grant
- 2006-07-10 US US11/484,247 patent/US7932372B2/en not_active Ceased
- 2006-07-31 EC EC2006006741A patent/ECSP066741A/es unknown
- 2006-08-03 MA MA29232A patent/MA28430B1/fr unknown
- 2006-08-08 NO NO20063601A patent/NO342054B1/no unknown
- 2006-08-09 KR KR1020067016064A patent/KR101262032B1/ko active IP Right Grant
-
2007
- 2007-07-03 HK HK07107034.6A patent/HK1099695A1/xx unknown
- 2007-08-20 US US11/894,559 patent/US20080124339A1/en not_active Abandoned
-
2008
- 2008-06-06 JP JP2008149091A patent/JP4729076B2/ja active Active
-
2009
- 2009-11-16 JP JP2009260786A patent/JP5094818B2/ja active Active
-
2012
- 2012-07-10 JP JP2012154794A patent/JP5836896B2/ja active Active
-
2014
- 2014-03-19 US US14/219,900 patent/USRE45847E1/en active Active
-
2015
- 2015-07-10 JP JP2015138764A patent/JP6215875B2/ja active Active
-
2016
- 2016-03-31 US US15/086,930 patent/US10259872B2/en active Active
-
2017
- 2017-01-16 JP JP2017004899A patent/JP6423024B2/ja active Active
-
2018
- 2018-05-01 JP JP2018087973A patent/JP6637104B2/ja active Active
-
2019
- 2019-02-21 US US16/282,157 patent/US20190300605A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009005695A5 (ja) | ||
| JP2010042025A5 (ja) | ||
| CA2861793C (en) | Method of providing monoclonal auto-antibodies with desired specificity | |
| AU2008320987B2 (en) | Humanized antibodies against TL1A | |
| US10131709B2 (en) | Nucleic acid molecules encoding monoclonal antibodies specific for IL-22 | |
| JP2015502145A5 (ja) | ||
| CN112262156B (zh) | 抗her2抗体 | |
| JP2014534218A5 (ja) | ||
| JP2020535799A5 (ja) | ||
| JP6799076B2 (ja) | インターフェロンベータ抗体およびその使用 | |
| RU2014120755A (ru) | Иммуносвязующие агенты, направленные против tnf | |
| JP2016521540A (ja) | 炎症性腸疾患の診断及び治療方法 | |
| JP2012501670A5 (ja) | ||
| CA2822288A1 (en) | Anti-c5/c5a/c5adesr antibodies and fragments | |
| JP2011527899A5 (ja) | ||
| TW201127401A (en) | Compositions and methods for treating inflammatory disorders | |
| JP2022022994A (ja) | Ｔｌ１ａ抗体で炎症性腸疾患を処置する方法 | |
| JP2023540444A (ja) | 治療用抗体 | |
| JP2012505227A5 (ja) | ||
| US20230357391A1 (en) | Cd47 binding agents and uses thereof | |
| JP2020533953A5 (ja) | ||
| TW202233237A (zh) | 用於在治療ｎｌｒｃ４－ｇｏｆ炎性體病變中使用的雙特異性抗體 | |
| US20220267428A1 (en) | BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS | |
| IL301887A (en) | A true human antibody specific for interleukin 1 alpha | |
| JPWO2021188851A5 (ja) |